Zealand Pharma A/S (ZLDPF)
48.24
-2.27
(-4.49%)
USD |
OTCM |
Aug 24, 16:00
Zealand Pharma Enterprise Value : 1.219B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 1.219B |
| August 21, 2026 | 1.378B |
| August 20, 2026 | 1.342B |
| August 19, 2026 | 1.342B |
| August 18, 2026 | 1.277B |
| August 17, 2026 | 1.277B |
| August 14, 2026 | 1.530B |
| August 13, 2026 | 1.530B |
| August 12, 2026 | 1.468B |
| August 11, 2026 | 1.468B |
| August 10, 2026 | 1.377B |
| August 07, 2026 | 1.377B |
| August 06, 2026 | 1.168B |
| August 05, 2026 | 1.168B |
| August 04, 2026 | 1.168B |
| August 03, 2026 | 1.168B |
| July 31, 2026 | 1.100B |
| July 30, 2026 | 1.100B |
| July 29, 2026 | 1.100B |
| July 28, 2026 | 1.100B |
| July 27, 2026 | 994.69M |
| July 24, 2026 | 994.69M |
| July 23, 2026 | 994.35M |
| July 22, 2026 | 964.39M |
| July 21, 2026 | 1.028B |
| Date | Value |
|---|---|
| July 20, 2026 | 1.028B |
| July 17, 2026 | 958.39M |
| July 16, 2026 | 983.52M |
| July 15, 2026 | 983.52M |
| July 14, 2026 | 983.52M |
| July 13, 2026 | 983.52M |
| July 10, 2026 | 983.52M |
| July 09, 2026 | 983.52M |
| July 08, 2026 | 1.014B |
| July 07, 2026 | 1.014B |
| July 06, 2026 | 1.036B |
| July 02, 2026 | 1.129B |
| July 01, 2026 | 907.43M |
| June 30, 2026 | 907.43M |
| June 29, 2026 | 828.45M |
| June 26, 2026 | 883.94M |
| June 25, 2026 | 883.94M |
| June 24, 2026 | 883.94M |
| June 23, 2026 | 883.94M |
| June 22, 2026 | 1.016B |
| June 18, 2026 | 1.016B |
| June 17, 2026 | 1.035B |
| June 16, 2026 | 1.035B |
| June 15, 2026 | 1.013B |
| June 12, 2026 | 1.013B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Genmab A/S | 23.48B |
| Ascendis Pharma A/S | 16.13B |
| Bavarian Nordic A/S | 2.176B |
| Evaxion AS | 21.46M |
| Novo Nordisk A/S | 171.54B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 609.41M |
| Revenue (Quarterly) | 698.72M |
| Total Expenses (Quarterly) | 89.30M |
| EPS Diluted (Quarterly) | 8.610 |
| Gross Profit Margin (Quarterly) | 99.76% |
| Profit Margin (Quarterly) | 87.22% |
| Earnings Yield | 12.44% |
| Operating Earnings Yield | 10.70% |
| Normalized Earnings Yield | 12.53 |